Tumor Cell-Derived Microparticles for Intracellular Succinic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tumor treatments, including radiotherapy and chemotherapy, cause irreversible damage to patients and are challenged by drug resistance, while tumor immunotherapy products like monoclonal antibodies have limited scope and succinic acid's therapeutic potential is hindered by its water-soluble nature.
Innovation Solution
Development of tumor cell-derived microparticles loaded with succinic acid through electro-transformation or co-incubation methods, allowing for targeted drug delivery and enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If succinic acid is used as a therapeutic agent, then it can promote inflammatory factor release and enhance immune response, but its water-soluble nature prevents it from freely entering cells to exert its effects
Solution Approach 1:
The patent uses tumor cell-derived microparticles as an intermediary carrier to deliver succinic acid into cells. The microparticles naturally fuse with cell membranes, enabling succinic acid to enter cells without directly overcoming its water-solubility limitation. This mediator approach resolves the contradiction by providing an indirect delivery pathway that maintains therapeutic efficacy while bypassing the cell permeability barrier.
Solution Approach 2:
The patent changes the physical state and delivery parameters of succinic acid by loading it into microparticles. This transformation allows succinic acid to be delivered in a controlled manner with optimized concentration and timing, converting it from a freely diffusible but ineffective water-soluble compound into a targeted delivery system that achieves intracellular accumulation necessary for therapeutic effect.
2Reliability
If chemotherapy drugs are used to treat tumors, then tumor cells can be killed, but irreversible damage is caused to patients and drug resistance develops
Solution Approach 1:
The patent converts the previously harmful effect of uncontrolled systemic drug delivery into a beneficial targeted approach. By using tumor cell-derived microparticles as carriers, the system exploits the natural biology of tumor cells to deliver therapeutic agents specifically to tumor sites, transforming the harm of off-target effects and drug resistance into a benefit of selective tumor cell targeting while sparing healthy tissues.
Solution Approach 2:
The patent employs a self-service mechanism where tumor cells themselves are used to create the delivery vehicle. Tumor cell-derived microparticles are generated from the tumor cells' own biological processes, and these microparticles naturally target and enter tumor cells. This self-service approach eliminates the need for external targeting mechanisms and reduces harm to healthy cells, thereby preventing drug resistance development.
3Reliability
If monoclonal antibody-based immune checkpoint inhibitors are used for tumor immunotherapy, then antitumor activity is achieved, but the scope of application is limited
Solution Approach 1:
The patent creates a universal platform with broad applicability by using tumor cell-derived microparticles as a carrier system that can deliver multiple different therapeutic payloads. Unlike monoclonal antibodies that target specific markers, this microparticle platform can be loaded with various agents including succinic acid, chemotherapeutics, and immunomodulators, making it adaptable to different tumor types and treatment strategies while maintaining effective antitumor activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tumor cell-derived microparticles with succinic acid exhibit safer, more effective tumor targeting and broader applicability, improving survival rates and reducing treatment costs for various cancers.
Implementation Method 1
The tumor cell-derived microparticles are secreted by the tumor itself, and can be recognized and phagocytosed by tumor cells
Implementation Method 2
succinic acid, as a vital metabolite of the tricarboxylic acid cycle, can promote the release of inflammatory factors
Implementation Method 3
mixing the tumor cell-derived microparticle with succinic acid to obtain a mixture I, and subjecting the mixture I to electro-transformation and centrifugation
Implementation Method 4
subjecting the mixture I to electro-transformation and centrifugation to obtain the tumor cell-derived microparticle loaded with the succinic acid
Data Source
AI summary
The present disclosure relates to the technical field of biopharmaceuticals, and in particular to a tumor cell-derived microparticle loaded with succinic acid, a preparation method therefor, and use thereof. Provided is a tumor cell-derived microparticle loaded with succinic acid, which includes a tumor cell-derived microparticle and succinic acid loaded in the tumor cell-derived microparticle. Experimental data show that compared with the tumor cell-derived microparticle or succinic acid, the provided tumor cell-derived microparticle loaded with succinic acid has a significant therapeutic effect on various subcutaneous tumors in mice, thereby prolonging the survival time of the mice. The tumor cell-derived microparticle, as a drug carrier, has higher safety and more abundant sources, and is convenient for actual production operations. Furthermore, provided is a preparation method for the tumor cell-derived microparticle loaded with succinic acid, which greatly improves the drug-loading capacity of the microparticle.